Method and reagent for determining mRNA capping rate
By digesting mRNA:DNA hybrids with RNase H enzyme using a specific designed single-stranded oligonucleotide probe with RNase H enzyme, the problem of capping rate calculation deviation and data instability caused by nonspecific cleavage of RNase H enzyme is solved, and mRNA is achieved Accuracy and stability of capping rate determination.
Patent Information
- Application Number
- CN202310511121.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-08
- Publication Date
- 2024-11-08
AI Technical Summary
RNase H enzymes have nonspecific cleavage when determining mRNA capping rate, resulting in the generation of products of multiple lengths, resulting in deviations in capping rate calculation, instability in data analysis and difficulty in judging impurities.
A single-stranded oligonucleotide probe is used to complement the 5' end part of mRNA in reverse. The probe consists of the 5' end DNA region and the 3' end RNA region. The DNA region is composed of 4 or 5 deoxyribonucleotides, and the RNA is The region consists of 6-70 ribonucleotides, RNA:DNA hybrids are digested by RNase H, and the mRNA 5' end fragments are isolated and analyzed, and the proportion of mRNA 5' end fragments containing Cap 1 structure accounts for all fragments.
It improves the cleavage uniformity and stability of RNase H enzyme, ensures the accuracy and stability of capping rate determination, and reduces the instability of data analysis.
Smart Images

Figure CN118910222A_ABST
Abstract
Description
Technical Field
[0001] In general, the present invention relates to the determination of mRNA capping rate. In particular, the present invention relates to improved methods and probes for determining mRNA capping rate. Background Art
[0002] In eukaryotic cells, messenger RNA (mRNA) has a 5' cap structure, which plays a key role in many biological processes. The cap structure is a very important component that can protect mRNA from damage by ribozymes, improve the stability of mRNA, and prolong the half-life of mRNA [1-3]; it helps mRNA recruit proteins and promote protein translation, and is an essential component for the initiation of translation [4-6].
[0003] There are two ways to artificially obtain capped mRNA. The first method is co-transcriptional capping, that is, during the transcription process, the cap structure analog is directly added to the reaction solution, and is added to the 5' end of the mRNA by the RNA polymerase with low substrate specificity, directly producing the corresponding capped mRNA [9,10]. Recently, TriLink has developed a novel co-transcriptional capping method-CleanCap, which starts with 5'AU. It can obtain mRNA with a capping rate of up to 90-99%, simplifying the mRNA preparation process and shortening the development time
[11] . The second method is enzymatic capping, which is the most commonly used capping method in industry. Generally, the in vitro transcription product (uncapped mRNA) is treated with vaccinia virus capping enzyme (VCE) and 2′-O-methyltransferase to form the final Cap1 cap structure. The vaccinia virus capping enzyme contains three enzyme activities (TPase, Gtase and G-N7 Mtase) [7,8]. Figure 1 As shown, the intermediate products formed during the capping process constitute impurities and are called PPP, PP, G Cap and Cap0 respectively.
[0004] The determination of mRNA capping rate is also a key indicator for the quality analysis of mRNA production process. There are currently many methods for determining the 5' end cap structure. In 2016, Michael Beverly et al. published an article using RNase H enzyme, biotin magnetic beads and LC-MS to determine the 5' end cap structure. Figure 2 As shown in the figure, a biotin-TEG labeled probe was designed for the 5' end of mRNA. After RNase H enzymatic cleavage and magnetic bead separation, short 5' end nucleic acid fragments with or without cap structures were obtained. LC-MS was used for detection and quantitative analysis of the proportion of each component to obtain the capping rate
[12] .
[0005] RNase H enzyme is a nuclease that can specifically cleave RNA in RNA:DNA double strands. RNase H enzyme activity was first discovered in calf thymus by Peter Hausen's group in 1969 [13,14]. Later, the first genes encoding bacterial RNase HI and RNase HII enzymes were found in Escherichia coli [15,16]. RNase H enzymes are divided into type 1 and type 2 based on amino acid sequence similarity, structure and substrate specificity [17,18]. RNase H1 and RNase H2 enzymes play important roles in DNA replication, repair and transcription. Mutations in the human RNase H2 complex can lead to immune dysfunction [19,20,21]. The RNase H1 derived from Escherichia coli is used in the present invention. Summary of the invention
[0006] Technical issues
[0007] RNase H is an endonuclease that 2+ In the presence of ions, it can specifically hydrolyze RNA in the DNA / RNA hybrid chain to generate 5′-phosphate and 3′-hydroxyl groups [22,23]. However, as shown in Figure 3, RNase H enzyme has non-specific cleavage, that is, cleavage can occur at multiple sites, resulting in products of various lengths (differences of several nucleotides). This phenomenon causes a variety of adverse effects: First, due to the multiple cleavage sites of RNase H enzyme, the capping rate calculated based on each cleavage site is biased, and an accurate final result cannot be obtained. As shown in Table 1, when using Probe2, there are three main cleavage sites; the capping rates obtained based on different enzyme cleavage sites are quite different. Second, whether it is the same batch or different batches of mRNA, the cleavage site of RNase H enzyme is unstable when different batches are processed with the same probe, resulting in instability in data analysis. As Figure 4 As shown in Table 2, when Probe1 is used, different results are obtained when the same batch of mRNA is processed with the same probe in different batches. Third, it affects the judgment of impurities. For example, the restriction sites of DNA / RNA hybrids are at the left and right ends of G. Combining different 5' end forms, components with similar molecular weights are formed, and structural analysis will be affected. As shown in Table 2, when Probe1 is used, the molecular weight of the product of cutting PP impurity at position -2 and the product of cutting G Cap impurity at position -3 are similar. When extracting impurity components, they will interfere with each other and cannot be accurately quantified.
[0008] Table 1: Calculation of capping rates for the three main cleavage sites of the same sample
[0009] Cleavage site PP PPP G Cap Cap 0 Cap 1 0 4.7% 6.3% 1.5% 0.8% 86.7% -1 4.9% 7.9% 1.4% 0.9% 84.9% -2 4.8% 3.1% 1.7% 0.2% 90.1%
[0010] Table 2: Molecular weight and extraction m / z(-4) of PP and G Cap
[0011]
[0012]
[0013] Technical Solution
[0014] The present invention provides a method for determining the capping rate of mRNA in an mRNA sample, comprising: annealing mRNA with a single-stranded oligonucleotide probe to generate an RNA:DNA hybrid;
[0015] The RNA:DNA hybrids were digested with RNase H to generate mRNA 5′ end fragments;
[0016] Isolation of mRNA 5' end fragments;
[0017] Analyze mRNA 5' end fragments; and
[0018] The ratio of the mRNA 5' end fragment containing the Cap 1 structure to all mRNA 5' end fragments is calculated, wherein the single-stranded oligonucleotide probe is reverse complementary to the 5' end portion of the mRNA, and the single-stranded oligonucleotide probe consists of a 5' end DNA region and a 3' end RNA region, the 5' end DNA region consists of 4 or 5 deoxyribonucleotides, and the 3' end RNA region consists of 6-70 ribonucleotides.
[0019] The present invention provides use of a single-stranded oligonucleotide probe in determining the capping rate of mRNA in an mRNA sample, wherein the single-stranded oligonucleotide probe is reverse complementary to the 5' end portion of the mRNA, and the single-stranded oligonucleotide probe consists of a 5' end DNA region and a 3' end RNA region, the 5' end DNA region consists of 4 or 5 deoxyribonucleotides, and the 3' end RNA region consists of 6-70 ribonucleotides.
[0020] In one embodiment, the 5' terminal DNA region consists of 4 deoxyribonucleotides.
[0021] In one embodiment, the 3' terminal RNA region consists of 7-65, 8-60, 9-55, 10-50, 11-45, 12-40, 13-35, 14-30, 15-25 or 18-22 ribonucleotides. 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 ribonucleotides.
[0022] In one embodiment, the 3' terminal base of the single-stranded oligonucleotide probe reaches the 5' terminal base of the mRNA and is paired. In one embodiment, the 3' terminal base of the single-stranded oligonucleotide probe does not reach or exceeds the 5' terminal base of the mRNA by one or more bases, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 bases or more.
[0023] In one embodiment, the probe is labeled with biotin at the 3' end. In one embodiment, the separation step utilizes avidin-coated magnetic beads.
[0024] In one embodiment, the analyzing step comprises one or more selected from the group consisting of gel electrophoresis, capillary electrophoresis, liquid chromatography (LC) and mass spectrometry (MS). In one embodiment, the liquid chromatography (LC) is high performance liquid chromatography (HPLC). In one embodiment, wherein the HPLC is HPLC-UV. In one embodiment, the mass spectrometry is electrospray-ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption-ionization mass spectrometry (MALDI-MS). In one embodiment, the analyzing step utilizes LC-MS. In one embodiment, the calculating step utilizes the peak area of the MS spectrum.
[0025] In one embodiment, the capping rate is calculated according to the following formula:
[0026]
[0027] The total peak area is the sum of the peak areas of the corresponding peaks of each 5' end structure.
[0028] In one embodiment, the annealing step comprises incubating at about 95°C for about 5 minutes, cooling to about 65°C in about 2 minutes, cooling to about 55°C in about 2 minutes, cooling to about 40°C in about 2 minutes, and cooling to about 22°C in about 2 minutes.
[0029] In one embodiment, the method further comprises: performing correction using a reference sample with a known capping rate.
[0030] In one embodiment, the mRNA sample is a sample prepared by in vitro transcription. In one embodiment, the mRNA is a therapeutic mRNA.
[0031] In one embodiment, the deoxyribonucleotide is a locked nucleic acid (LNA).In one embodiment, the ribonucleotide is a 2'-O-Me ribonucleotide.
[0032] In one embodiment, prior to the digestion, the mRNA sample is mixed with an annealing buffer containing at least one component selected from the group consisting of urea, EDTA, magnesium chloride, and Tris. In one embodiment, the mRNA sample and the annealing buffer are incubated at a high temperature to denature the mRNA.
[0033] In one embodiment, the method further comprises: after the digestion, incubating the mRNA sample with 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) to produce a CNP-treated mRNA sample. In one embodiment, the mRNA sample is incubated with 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) for about 1 hour.
[0034] In one embodiment, the method further comprises: incubating the CNP-treated mRNA sample with calf intestinal alkaline phosphatase (CIP).
[0035] In one embodiment, the method further comprises: incubating the mRNA sample with an enzyme inhibitor to stop the enzymatic activity of the RNase H. In one embodiment, the enzyme inhibitor is EDTA.
[0036] In one embodiment, the method achieves a cleavage efficiency of at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% at the dominant cleavage site. In one embodiment, the cleavage efficiency of each site is calculated according to the following formula:
[0037]
[0038] The total peak area is the sum of the peak areas of the corresponding peaks at each cleavage site.
[0039] Technical Effects
[0040] The present invention improves the cutting uniformity and stability of RNase H enzyme, solves various adverse effects caused by multiple cleavage sites of RNase H enzyme, improves the response of the main cleavage site, and improves the accuracy and stability of data analysis. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 is a schematic diagram showing the enzymatic capping rate process.
[0042] Figure 2 is a schematic diagram showing a method for determining mRNA capping rate.
[0043] Figures 3A-3D Example showing non-specific cleavage by RNase H. Figure 3A It is a schematic diagram of RNase H cleaving RNA, where: "↓" indicates the position where RNase H cleaves RNA (cleavage efficiency is above 5%), the length of the arrow represents the cleavage frequency, and the longer the arrow, the higher the frequency; "●" represents the biotin label at the 3′ end of the probe; bold and underlined deoxyribonucleotides. Figure 3B-3D The mass spectrum of the cleavage product is shown.
[0044] Figure 4 An example showing the instability of RNase H cleavage, showing the mass spectra of products from different batches of the same mRNA treated with the same probe.
[0045] Figure 5 It is a schematic diagram showing the numbering method of the cleavage sites, where: "▽" represents the cleavage site of RNase H enzyme on RNA, with 0 as the center, extending one base to the 3' end is +1, extending one base to the 5' end is -1, and so on; "●" represents the biotin label at the 3' end of the probe; bold and underlined deoxyribonucleotides.
[0046] Figures 6A-6F Results of an exemplary embodiment of a preliminary exploration of probe optimization are shown. Fig. 6A It is a schematic diagram of RNase H cleaving RNA, where: "↓" indicates the position where RNase H cleaves RNA (cleavage efficiency is above 5%), the length of the arrow represents the cleavage frequency, and the longer the arrow, the higher the frequency; "●" represents the biotin label at the 3′ end of the probe; bold and underlined deoxyribonucleotides. Figure 6B Displays the cutting efficiency of each point. Figure 6C-6F The mass spectrum of the cleavage product is shown.
[0047] Figure 7Results of an exemplary embodiment of optimizing the number of deoxyribonucleotides in a probe are shown.
[0048] Figure 8 Results of an exemplary embodiment of optimizing deoxyribonucleotide positions in a probe are shown.
[0049] Fig. 9 Results for an exemplary embodiment of optimizing probe length are shown.
[0050] Figures 10A-10F Results for an exemplary embodiment of probe optimization for commonly used 5' end sequences are shown. Fig. 10A It is a schematic diagram of RNase H cleaving RNA, where: "↓" indicates the position where RNase H cleaves RNA (cleavage efficiency is above 5%), the length of the arrow represents the cleavage frequency, and the longer the arrow, the higher the frequency; "●" represents the biotin label at the 3′ end of the probe; bold and underlined deoxyribonucleotides. Fig. 10B Displays the cutting efficiency of each point. Figures 10C-10F The mass spectrum of the cleavage product is shown. DETAILED DESCRIPTION
[0051] the term
[0052] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.
[0053] The term "nucleobase" encompasses purines and pyrimidines, including the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural or synthetic analogs or derivatives thereof.
[0054] The term "functional nucleotide analogue" refers to a modified form of a canonical nucleotide A, G, C, U or T, which (a) retains the base pairing properties of the corresponding canonical nucleotide, and (b) comprises at least one chemical modification of any combination of (i) to (iii) of (i) a nucleobase, (ii) a sugar group, (iii) a phosphate group or (iv) a corresponding natural nucleotide. As described herein, base pairs not only cover standard Watson-Crick AT, AU or CG base pairs, but also include base pairs formed between canonical nucleotides and functional nucleotide analogs or between a pair of functional nucleotide analogs, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors allows the formation of hydrogen bonds between the modified nucleobase and the standard nucleobase or between two complementary modified nucleobase structures. For example, a functional analogue of guanosine (G) retains the ability to base pair with a functional analogue of cytosine (C) or cytosine. An example of this non-canonical base pairing is base pairing between a modified nucleotide inosine and adenine, cytosine or uracil. Functional nucleotide analogs can be naturally occurring or non-naturally occurring. Thus, a nucleic acid molecule comprising a functional nucleotide analog may have at least one modified nucleobase, sugar group, or internucleoside linkage.Exemplary chemical modifications to nucleobases, sugar groups, or internucleoside linkages of nucleic acid molecules are provided herein.
[0055] Unless otherwise indicated, the term "about" refers to an acceptable error for a particular value determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term "about" refers to within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term "about" refers to within 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.05%, or less of a given value or range.
[0056] 1. Experimental Methods
[0057] 1. mRNA Preparation
[0058] mRNA was prepared by standard in vitro transcription protocol (see CN113874507A). In vitro transcribed mRNA was treated with vaccinia virus capping system (Part#GMP-VCS-VE101, Kaixia Biotechnology, China) and 2′-O-methyltransferase (Part#GMP-MEH-VE101, Kaixia Biotechnology, China) for capping. Capped mRNA was dissolved in nuclease-free water. The length and integrity of the final mRNA were confirmed by capillary electrophoresis (Fragment Analzyer 5300, MA).
[0059] 2. Probe Design
[0060] Design and synthesize probes based on the mRNA sequence. See the Appendix for the sequences of the mRNA and probes used for testing.
[0061] 3. Preprocessing
[0062] 400 pmol of probe and 200 pmol of mRNA were mixed in 36 μL of annealing buffer (Biyuntian, R0051), and then the volume was made up to 180 μL with nuclease-free water. The mixture was denatured at 95°C for 5 minutes in a PCR instrument, and then cooled to 65°C, 55°C, 40°C, and finally 22°C every 2 minutes to achieve annealing of the probe and mRNA
[12] .
[0063] 4. RNase H cleavage
[0064] Take 100 μL DynabeadsTMMyOneTMStreptavidin C1 (Part#35002D, Thermo, USA) and activate the magnetic beads according to the Invitrogen method. Before use, let the magnetic beads stand in the magnetic stand for 5 minutes and remove the supernatant. Add the annealing mixture of mRNA and probe, mix by pipetting, and incubate at room temperature for 30 minutes. Add 10 μL RNase H enzyme (Part#M0297L, New England Biolabs, USA), mix by pipetting, and incubate at 37°C for 3 hours. Remove the supernatant, wash four times with 100 μL washing buffer (5mM Tris-HCl, pH 7.5; 0.5mM EDTA; 1M NaCl), and then wash three times with 100 μL nuclease-free water. Add 100 μL 75% methanol and heat to 80°C to release mRNA from the probe. The supernatant was removed, dried in a desiccator, and dissolved in a blank solvent (100 μM EDTA; 1% MeOH). The cleavage product was analyzed using a liquid spectrometer (Agilent, Qtof-6545XT)
[12] .
[0065] 2. Data Analysis
[0066] 1. Cap rate
[0067] Record the peak area of each 5' end structure on the mass spectrum.
[0068] The capping rate is calculated according to the following formula:
[0069]
[0070] The total peak area is the sum of the peak areas of the corresponding peaks of each 5' end structure.
[0071] 2. Cutting efficiency
[0072] Record the peak area of each cleavage site on the mass spectrum.
[0073] The cutting efficiency of each site was calculated according to the following formula:
[0074]
[0075] The total peak area is the sum of the peak areas of the corresponding peaks at each cleavage site.
[0076] 3. Experimental Results
[0077] 1. Preliminary exploration of probe optimization
[0078] Using the same mRNA (mRNA1), we preliminarily explored the effect of probes (Probe1 series) on the detection of capping rates. The results are shown in Figures 6A-6F and Table 3.
[0079] For probes Probe1-7b-1 and Probe1-7b-2, no cleavage products were detected.
[0080] Probe1 was designed based on the literature
[12] , with a maximum cleavage efficiency of 49.82%. The highest cleavage efficiencies of the other five probes were 99.67% (Probe1-24b-1), 73.93% (Probe1-24b-2), 95.57% (Probe1-24b-3), 55.79% (Probe1-20b-1), and 99.46% (Probe1-20b-2), all higher than Probe1.
[0081] The length of the cleavage product affects the detection of the capping rate. The peak areas (Cap1) are 18052515 (Probe1), 45774170 (Probe1-24b-1), 35056233 (Probe1-24b-2), 45340644 (Probe1-24b-3), 387121 (Probe1-20b-1) and 6204599 (Probe1-20b-2).
[0082] The proportion of each 5' end structure after capping was calculated based on the main cleavage site. As shown in Table 3, the proportion of each 5' end structure was different when using different probes for detection.
[0083] Table 3: Effect of probes on detection of 5' end structure ratio
[0084] Probe Area(Cap1) PP PPP G Cap Cap 0 Cap 1 Probe1 18052515 4.7% 6.3% 1.5% 0.8% 86.7% Probe1-24b-1 45774170 4.6% 3.7% 1.5% 0.3% 90.0% Probe1-24b-2 35056233 4.5% 3.4% 1.4% 0.3% 90.5% Probe1-24b-3 45340644 6.0% 5.1% 0.0% 0.0% 88.9% Probe1-20b-1 387121 4.9% 3.7% 1.2% 0.2% 90.1% Probe1-20b-2 6204599 4.7% 6.3% 1.5% 0.8% 86.7%
[0085] 2. Multi-factor exploration
[0086] Two mRNAs with large differences in 5' end sequences (mRNA1 and mRNA2, used in Probe1 series and Probe7 series, respectively) were used to deeply explore the effects of multiple probe factors on the detection capping rate.
[0087] 2.1 Number of deoxyribonucleotides in the probe
[0088] In probe design, six deoxyribonucleotides are often placed at the 5' end
[12] . We reduced the number of deoxyribonucleotides at the 5' end of the probe to 5 or 4. The results are shown in Figure 7 and Table 4.
[0089] For both mRNAs, the enzyme cleavage uniformity of the probe with 4 deoxyribonucleotides was higher than that of other probes.
[0090] Table 4: Effect of the number of deoxyribonucleotides on cutting (bold indicates the highest cutting efficiency ratio)
[0091]
[0092] 2.2 Position of deoxyribonucleotides in the probe
[0093] The preliminary exploration has included three probes for studying the positions of deoxyribonucleotides, namely Probe1-24b-1, Probe1-24b-2 and Probe1-24b-3. Their enzyme cleavage uniformity is higher than that of Probe1, among which Probe1-24b-1 has the highest Cap1 response and enzyme cleavage uniformity.
[0094] On the basis of 2.1, 4 deoxyribonucleotides were retained to explore the position of deoxyribonucleotides in the probe. The results are shown in Figure 8 and Table 5.
[0095] Probe1-24b-1 and Probe7-24-4D-0 have the highest enzyme cleavage uniformity. The common point of these two probes is that they retain 4 deoxyribonucleotides at the end of the 5' end.
[0096] Table 5: Effect of the position of deoxyribonucleotides on cutting (bold indicates the highest cutting efficiency ratio)
[0097]
[0098]
[0099] 2.3 Probe length
[0100] Based on 2.1 and 2.2, the length of the probe was explored. The results are shown in Fig. 9 and Table 6.
[0101] Probes with lengths ranging from 10 to 70 bases all performed better than the original probes.
[0102] Table 6: Effect of probe length on cutting (bold indicates the highest cutting efficiency ratio)
[0103]
[0104]
[0105] 3. Applicability study
[0106] like Fig. 10A As shown, 5 commonly used 5' end sequences were selected and the corresponding probes were designed. The probe before optimization (containing 6 DNA bases) was used as a control. The results are shown in Fig. 10B and Figures 10C-10F The highest cutting efficiencies of Probe2-4D, Probe3-4D, Probe4-4D, Probe6-4D and Probe6-20b-4D were 99.76%, 98.03%, 99.15%, 84.11% and 68.12%, respectively, which were higher than the corresponding Probe2, Probe3, Probe4 and Probe6 of 61.13%, 44.82%, 72.43% and 29.11%.
[0107] 4. Stability study
[0108] Eight parallel reactions were performed using mRNA1 and Probe1-24b-1. The cleavage efficiency of each site was determined, and the results are shown in Table 7. The highest cleavage efficiency occurred at the "0" site. As shown in Table 9, the standard deviation was 0.053 and the coefficient of variation was 0.0005. The proportion of each component in the capping process was calculated based on the site with the highest cleavage efficiency, and the results are shown in Table 8. Cap1 has a high and stable proportion. As shown in Table 9, the standard deviation is 0.060 and the coefficient of variation is 0.0006.
[0109] Table 7: Cutting efficiency ratio of each cutting site (bold indicates the highest cutting efficiency ratio)
[0110]
[0111] Table 8: Proportion of each 5' end structure (bold indicates the highest structure proportion)
[0112]
[0113]
[0114] Table 9: Statistical analysis
[0115] Cutting efficiency (Table 7) Cap1 proportion (Table 8) average value 99.73% 93.95% Standard Deviation 0.053 0.060 Coefficient of variation 0.0005 0.0006
[0116] References
[0117] 1. Furuichi Y, LaFiandra A, Shatkin AJ. 5′-Terminal structure and mRNA stability. Nature. 1977;266(5599):235-9.
[0118] 2. Coutts M, Krowczynska A, Brawerman G. Protection of mRNA against nucleases in cytoplasmic extracts of mouse sarcoma ascites cells. Biochim Biophys Acta. 1993;1173(1):49-56.
[0119] 3. Zuoren Wang, Xinfu Jiao, Anne Carr-Schmid, and Megerditch Kiledjian. The hDcp2 protein is a mammalian mRNA decapping enzyme. PNAS. 2002;99:12663-12668.
[0120] 4. Furuichi Y, Shatkin AJ. Viral and cellular mRNA capping: past and prospects. Adv Virus Res. 2000;55:135-184.
[0121] 5. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136:731-745.
[0122] 6. Michaela Müller-McNicoll, Karla M Neugebauer. How cells get the message: dynamic assembly and function of mRNA-protein complexes. Nat Rev Genet. 2013;14:275-287.
[0123] 7.Shuman S.Structure,mechanism,and evolution of the mRNA cappingapparatus.Prog Nucleic Acid Res Mol Biol.2001;66:1-40.
[0124] 8.Fabrega C,Hausmann S,Shen V,Shuman,S,Lima CD.Structure andMechanism of mRNA Cap(Guanine-N7)Methyltransferase.Molecular Cell.2004;13:77-89.
[0125] 9.Hadas Y,Sultana N,Youssef E,Sharkar M,Kaur K,Chepurko E,ZangiL.Optimizing modified mRNA in vitro synthesis protocol for heart genetherapy.Molecular Therapy Methods&Clinical Development.2019;14:300-305.
[0126] 10.Sikorski PJ,Warminski M,Kubacka D,Ratajczak T,Nowis D,Kowalska J,Jemielity J.The identity and methylation status of the first transcribednucleotide in eukaryotic mRNA 5’cap modulates protein expression in livingcells.Nucleic Acids Research.2020;48(4):1607-1626.
[0127] 11.Henderson J M,Ujita A,Hill E.Cap 1Messenger RNA Synthesis with Co-transcriptional Analog by In Vitro Transcription.Currentprotocols.2021;1(2):e39.
[0128] 12.Beverly M,Dell A,Parmar P.Label-free analysis of mRNA cappingefficiency using RNase H probes and LC-MS.Analytical and bioanalyticalchemistry.2016;408(18):5021-5030.
[0129] 13.Stein H,Hausen P.Enzyme from calf thymus degrading the RNA moietyof DNA-RNAHybrids:effect on DNA-dependent RNA polymerase.Science.1969;166:393-395.
[0130] 14.Hausen P,Stein H.Ribonuclease H.An enzyme degrading the RNA moietyof DNA-RNA hybrids.Eur J Biochem.1970;14:278-283.
[0131] 15.Kanaya S,Crouch RJ.DNA sequence of the gene coding for Escherichiacoli ribonuclease H.J Biol Chem.1983;258:1276-1281.
[0132] 16.Itaya M.Isolation and characterization of a second RNase H(RNaseHII)of Escherichia coli K-12 encoded by the rnhB gene.PNAS.1990;87:8587-8591.
[0133] 17.Ohtani N,Haruki M,Morikawa M,Crouch RJ,Itaya M,KanayaS.Identification of the genes encoding Mn 2+ -dependent RNase HII and Mg 2+ -dependent RNase HIII from Bacillus subtilis:classification of RNases H intothree families.Biochemistry.1999a;38:605-618.
[0134] 18.Crouch RJ,Arudchandran A,Cerritelli SM.RNase H1 of Saccharomycescerevisiae:methods and nomenclature.Methods Enzymol.2001;341:395-413.
[0135] 19. Crow YJ, Leitch A, Hayward BE, Garner A, Parmar R, Griffith E, Ali M, Semple C, Aicardi J, Babul-Hirji R, Baumann C, Baxter P, Bertini E, Chandler KE, Chitayat D, Cau D, Dery C, Fazzi E, Goizet C, King MD, Klepper J, Lacombe D, Lanzi G, Lyall H, Martinez-Frias ML, Mathieu M, McKeown C, Monier A, Oade Y, Quarrell OW, Rittey CD, Rogers RC, Sanchis A, Stephenson JB, Tacke U, Till M, Tolmie JL, Tomlin P, Voit T, Weschke B, Woods CG, Lebon P, Bonthron DT, Ponting CP, Jackson AP. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection.NatGenet.2006b;38:910-916.
[0136] 20.Ramantani G,Kohlhase J,Hertzberg C,Innes AM,Engel K,Hunger S,Borozdin W,Mah JK,Ungerath K,Walkenhorst H,Richardt HH,Buckard J,Bevot A,Siegel C,von Stulpnagel C,Ikonomidou C,Thomas K,Proud V,Niemann F,WieczorekD,Hausler M,Niggemann P,Baltaci V,Conrad K,Lebon P,Lee-Kirsch MA.Expandingthe phenotypic spectrum of lupuserythematosus in aicardi-goutieressyndrome.Arthritis Rheum.2010;62(5):1469-1477.
[0137] 21.Hollis T,Shaban NM.Structure and function of RNase Henzymes.Ribonucleases.2011;26:299-317.
[0138] 22.Miller HI,Riggs AD,Gill GN.Ribonuclease H(hybrid)in Escherichiacoli:Identification and characterization[J].Journal of BiologicalChemistry.1973;248(7):2621-2624.
[0139] 23.Berkower I,Leis J,Hurwitz J.Isolation and characterization of anendonuclease from Escherichia coli specific for ribonucleic acid inribonucleic acid·deoxyribonucleic acid hybrid structures.Journal ofBiological Chemistry.1973;248(17):5914-5921.
[0140] sequence
[0141] Probe sequence
[0142]
[0143]
[0144] Note: "d" in front refers to deoxyribonucleotide; " m ” refers to 2'-O-methylribose-modified RNA; all probes were labeled with biotin-TEG at the 3' end.
[0145] mRNA sequences
[0146] mRNA-1 (corresponding to probe 1) (SEQ ID NO: 48):
[0147]
[0148] mRNA-2 (corresponding to probe 7) (SEQ ID NO: 49):
[0149]
[0150]
Claims
1. A method for determining the capping rate of mRNA in an mRNA sample, comprising: annealing the mRNA to a single-stranded oligonucleotide probe to generate an RNA:DNA hybrid; The RNA:DNA hybrids were digested with RNase H to generate mRNA 5′ end fragments; Isolation of mRNA 5' end fragments; Analyze mRNA 5' end fragments; and The ratio of the mRNA 5' end fragment containing the Cap 1 structure to all mRNA 5' end fragments is calculated, wherein the single-stranded oligonucleotide probe is reverse complementary to the 5' end portion of the mRNA, the single-stranded oligonucleotide probe consists of a 5' end DNA region and a 3' end RNA region, the 5' end DNA region consists of 4 or 5 deoxyribonucleotides, and the 3' end RNA region consists of 6-70 ribonucleotides.
2. The method of claim 1, wherein the 5' end DNA region consists of 4 deoxyribonucleotides.
3. The method of claim 1, wherein the 3' end RNA region consists of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 or 70 ribonucleotides.
4. The method of claim 1, wherein the probe is labeled with biotin at the 3' end, and wherein the separation step utilizes avidin-coated magnetic beads.
5. The method of claim 1, wherein the analyzing step comprises one or more selected from the group consisting of gel electrophoresis, capillary electrophoresis, liquid chromatography (LC) and mass spectrometry (MS).
6. The method of claim 5, wherein the liquid chromatography (LC) is high performance liquid chromatography (HPLC).
7. The method of claim 5, wherein the mass spectrometry is electrospray-ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption-ionization mass spectrometry (MALDI-MS).
8. The method of claim 1, wherein the analyzing step utilizes LC-MS.
9. The method of claim 8, wherein the calculating step utilizes peak areas of MS spectra.
10. The method of claim 1, wherein the mRNA sample is a sample prepared by in vitro transcription, and / or wherein the mRNA is a therapeutic mRNA.
11. Use of a single-stranded oligonucleotide probe in determining the capping rate of mRNA in an mRNA sample, wherein The single-stranded oligonucleotide probe is reverse complementary to the 5' end of the mRNA, and consists of a 5' end DNA region and a 3' end RNA region, wherein the 5' end DNA region consists of 4 or 5 deoxyribonucleotides, and the 3' end RNA region consists of 6-70 ribonucleotides.
